This technology is a stable, intranasal dry powder formulation of levothyroxine free acid designed to improve absorption and avoid degradation, offering a more reliable alternative to oral thyroid hormone therapy for hypothyroidism.
Hypothyroidism is a prevalent endocrine disorder affecting approximately 9 to 11 percent of the global population. Managing this chronic condition necessitates lifelong thyroid hormone replacement therapy to maintain normal metabolic functions. Because thyroid hormones possess a very narrow therapeutic index, minor deviations in blood levels can lead to significant clinical consequences. Consequently, there is a critical medical need for a highly reliable, patient-friendly drug delivery system that ensures precise systemic absorption and maintains stable hormone concentrations over time.
Current standard treatments rely on the oral administration of levothyroxine sodium pentahydrate, which presents substantial clinical challenges. Oral therapies suffer from highly variable bioavailability, ranging between 40 and 80 percent, and require strict administration on an empty stomach to prevent food and drug interactions. These stringent regimens frequently result in poor patient adherence and erratic hormone levels. Furthermore, attempting to bypass the gastrointestinal tract using standard liquid formulations introduces severe stability issues, as levothyroxine undergoes rapid chemical degradation in aqueous environments. Additionally, standard salt forms are highly hygroscopic, making them vulnerable to moisture-induced degradation and severely limiting their permeation capabilities across mucosal barriers.
This therapeutic solution is an intranasal dry powder formulation utilizing levothyroxine free acid (LFA) for managing hypothyroidism. Unlike traditional liquid sprays, this technology employs a dry powder delivery system to prevent the rapid chemical degradation levothyroxine experiences in aqueous environments. The formulation integrates specialized solubility and permeation enhancers tailored to the unique morphology of LFA particles. By delivering the medication directly across the nasal mucosa, the system provides an alternative administration route that avoids the gastrointestinal tract while maintaining the long-term chemical integrity of the active ingredient.
This technology is highly differentiated from standard oral therapies by overcoming their variable bioavailability and strict empty-stomach administration requirements. Utilizing the free acid form instead of traditional levothyroxine sodium pentahydrate provides superior solid-state stability due to significantly lower hygroscopicity, which minimizes moisture-induced degradation during storage. Furthermore, LFA demonstrates nearly double the mucosal permeation compared to standard salt forms. By shifting to an intranasal dry powder format, this solution eliminates food-drug interactions and inconsistent hormone levels, offering a highly stable, reliable, and patient-friendly approach to lifelong thyroid hormone replacement therapy.
This patent is available for exclusive licensing.
This technology utilizes levothyroxine free acid in a dry powder format for intranasal delivery. By employing a solid-state formulation, it bypasses chemical degradation inherent in aqueous solutions. The free acid form offers lower hygroscopicity and superior mucosal permeation compared to levothyroxine sodium pentahydrate. Integrating solubility and permeation enhancers, this system optimizes drug transport across the nasal mucosa, ensuring consistent bioavailability and stability for thyroid hormone replacement therapy.
Provisional patent 64/030,982 filed 04/06/26